Epinephrine-producing cells are characterized by the presence of phenylethanolamine N-methyltransferase (PNMT), which catalyzes the formation of epinephrine from norepinephrine. We generated a line of transgenic mice carrying a chimeric gene containing human PNMT cDNA fused to the 4-kilobase fragment of the human dopamine ,B-hydroxylase (DBH) gene promoter, to switch catecholamine phenotype in the nervous and endocrine systems. Human PNMT transcripts and immunoreactivity were mainly detected in norepi-
nephrine neurons in brain and sympathetic ganglion as well as in norepinephrine-producing cells in adrenal medulla of transgenic mice, indicating that the human DBH gene promoter of 4 kilobases is sufficient to direct expression of the gene in norepinephrine-producing cells. Analysis of catecholamines in the various tissues showed that the expression of human PNMT in transgenic mice induced the appearance of epinephrine in sympathetic ganglion and dramatic changes in norepinephrine and epinephrine levels in brain, adrenal gland, and blood. These results indicate that the additional PNMT expression in norepinephrine-producing cells can convert these cells to the epinephrine phenotype, and suggest that norepinephrineproducing cells normally possess the basic machinery required for the synthesis of epinephrine except for PNMT. Thus it appears that the only major difference between norepinephrine-and epinephrine-producing cells is the expression of PNMT. Our transgenic animals provide an experimental model to investigate the functional differences between norepinephrine and epinephrine.
The mammalian central and sympathetic nervous systems contain three kinds of catecholaminergic neuron (dopamine, norepinephrine, and epinephrine neurons), each of which is localized at distinct regions in the brain and ganglion and has separate physiological functions (1) . Adrenal medulla also consists of cells producing either norepinephrine or epinephrine as hormones. In the peripheral tissues, norepinephrine and epinephrine have similar functions in homeostatic regulation of various physiological actions including blood pressure, heart rate, carbohydrate and fatty acid metabolism, and respiration.
Catecholamines are synthesized from L-tyrosine by four kinds of enzyme: tyrosine hydroxylase (TH, EC 1.14.16.2), aromatic L-amino acid decarboxylase (AADC, EC 4.1.1.28), dopamine ,B-hydroxylase (DBH, EC 1.14.17.1), and phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28) (2) (3) (4) . TH catalyzes the formation of 3,4-dihydroxyphenylalanine (dopa) from L-tyrosine (5), and then AADC synthesizes dopamine with dopa as substrate (6) . These two enzymes are present in all catecholamine-producing cells. DBH is the copper-containing monooxygenase that catalyzes the hydroxylation of dopamine to norepinephrine (7, 8) . This enzyme is localized in both norepinephrine-and epinephrineproducing cells. Finally, PNMT is the methyltransferase that catalyzes the formation of epinephrine from norepinephrine with S-adenosyl-L-methionine as the methyl donor (9) and exists predominantly in epinephrine-producing cells. The catecholamine phenotype is thought to be determined by the cell type-specific and coordinated expression of the genes encoding the catecholamine-synthesizing enzymes.
The physiological functions of catecholamines and the signal transduction mechanism have been elucidated, but it is still unclear why three catecholamine phenotypes are required for the actions of the nervous and endocrine systems. If one ofthese catecholamine phenotypes could be artificially converted to the other phenotype, would any changes occur in the neurological and hormonal functions? As the initial step to answer this question, we have achieved the expression of PNMT under the control of the human DBH gene promoter in transgenic mice, to investigate whether the additional expression of PNMT in norepinephrine-producing cells could switch these cells to the epinephrine phenotype. The cell-type specificity of the promoter function driving the DBH gene was also analyzed.
EXPERIMENTAL PROCEDURES
Construction of Transgene. The 5' flanking region of the human DBH gene, which corresponds to the nucleotide sequence extending from the HindIII site at approximately -4.0 kilobases (kb) to the nucleotide + 12 downstream of the transcription initiation site, was derived from a genomic clone, gDBH-1 (10). The 2.0-kb DNA fragment containing the second intron and the polyadenylylation signal of the rabbit f3-globin gene and the polyadenylylation signal of simian virus 40 (SV40) early gene was derived from pKCRH2 (11) and subcloned between the BamHI and Sal I sites of Bluescript M13(+) to produce plasmid pBST-N. The EcoRI-EcoRI fragment containing human PNMT cDNA (12) was inserted into the EcoRI site of pBST-N. The 3.0-kb BamHI-Xho I fragment of the resulting plasmid was connected downstream of the human DBH gene promoter to generate pDPN (Fig. 1) .
Pronuclear Micro i ection. The 7.0-kb Xba I-Xho I fragment containing the transgene was microinjected into fertilized mouse eggs (C57BL/6 x C57BL/6), as described by Northern Blot Analysis. Total RNA was isolated from the tissues of mice by the guanidinium isothiocyanate/CsCl procedure (14) . RNA (20 ,ug per lane) was electrophoresed in a O.9o agarose gel containing formaldehyde and was transferred to a nylon filter. The filter was hybridized with 32P-labeled PNMT cDNA or mouse /3-actin cDNA (15) .
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis. Total RNA (2 ,ug) was reverse-transcribed with Moloney murine leukemia virus reverse transcriptase using oligo(dT) primer. Half of the cDNA synthesized was used for PCR amplification (16) with either the transgene primer set or the mouse f3-actin primer set. The transgene primer set was 5'-TACCTCCGCAACAACTACGC-3' (primer 1), which corresponds to nucleotides 103-122 of human PNMT cDNA (12) , and 5'-GCCAGAAGTCAGATGCT-CAA-3' (primer 2), which is complementary to nucleotides 1243-1262 of the rabbit ,3-globin sequence (17) . The mouse ,3-actin primer set was 5'-GCGAGCACAGCTTCTT-TGCA-3' (primer 1), which corresponds to nucleotides 22-41 of its cDNA (15) , and 5'-ACGCAGCTCAGTAACAGTCC-3' (primer 2), which is complementary to nucleotides 1211-1230 of ,3-actin cDNA.
Immunohistochemical Analysis. Immunostaining was carried out with anti-bovine PNMT antibody (18) and antihuman DBH-N antibody (19) by the peroxidase-antiperoxidase method. Anti-human DBH-N antibody was used to identify norepinephrine-and epinephrine-producing cells in the brain and adrenal gland.
Assay of PNMT Activity. Mice were anesthetized with pentobarbital, and tissues were removed. PNMT activity was measured according to Trocewicz et al. (20) . Epinephrine formed enzymatically was analyzed by high-performance liquid chromatography (HPLC) with electrochemical detection. Protein concentration was determined by the method of Bradford (21) with bovine gamma globulin as a standard.
Measurement of Catecholamine Content. Tissues removed were sonicated in 250 ,u of phosphate-buffered saline (PBS). Serum was prepared by centrifugation of blood collected from the posterior vena cava. Catecholamine content was measured as described by Mefford et al. (22) . Norepinephrine and epinephrine in each tissue were analyzed by HPLC-ECD with electrochemical detection. N-Methyldopamine or 3,4-dihydroxybenzylamine was used as internal standard.
RESULTS
Creation of Transgenic Mice Carrying a Human DBH Promoter-PNMT cDNA Fusion Gene. Fig. 1A summarizes our experimental strategy. Because DBH is expressed in both norepinephrine-and epinephrine-producing cells in wild-type mice, we selected the human DBH gene promoter to express PNMT in norepinephrine-producing cells. If the DBH promoter can function selectively, the additional expression of PNMT in norepinephrine-producing cells would cause the conversion of norepinephrine to epinephrine, and overproduction of PNMT in epinephrine-producing cells would also be expected. Fig. 1B shows the transgene construct used; it includes the 4-kb DNA fragment of human DBH promoter, in addition to the rabbit f3-globin second intron, human PNMT cDNA, rabbit P3-globin polyadenylylation signal, and SV40 early-gene polyadenylylation signal.
Microinjection of the DNA fragment into fertilized mouse eggs generated four female and four male founders with the transgene varying from 3 to 80 copies per haploid genome. RT-PCR analysis of total RNA extracted from eight founder mouse brains revealed that five of them expressed the transgene transcript. Moreover, adrenal glands of these five founders had PNMT activities 3-to 4-fold higher than those of nontransgenic control mice (data not shown). The male transgenic mouse designated DPN2-6 was used in this study, because this founder showed the highest PNMT activity in the adrenal gland. Offspring (7-12 weeks old) derived from DPN2-6 were subjected to the following analyses.
Analysis of Transgene mRNA Expression. Northern blot analysis with a human PNMT cDNA probe showed the expression of a single 1.8-kb mRNA in the brain of the transgenic mice ( Fig. 2A) . The size of the transgene RNA indicates that it is processed using only the SV40 polyadenylylation signal. We used RT-PCR to detect the transgene RNA expression in brain, adrenal gland, and SCG. As shown in Fig. 2B (Fig. 3  A-C) . The axon fibers of these neurons were also stained, indicating that the transgene product can be delivered by axonal flow to the fibers from the cell bodies. Transgenic brain showed PNMT immunoreactivity not only in norepinephrine and epinephrine neurons but also in some dopamine neurons (A10 and A16 nuclei) and in some noncatecholaminergic neurons of cortex, striatum, cerebellum, hippocampus, and olfactory bulb (unpublished data). In the adrenal gland of nontransgenic control mice, scattered epinephrine-producing cells were stained by anti-PNMT antibody, while almost all cells in the adrenal medulla of transgenic mice were stained with the same antibody, revealing the expression of the transgene product in norepinephrine-producing cells (Fig. 3 
D-F).
Catecholamine Metabolism in Transgenic Mice. In the brain of nontransgenic control mice, PNMT activity was detected only in the pons-medulla oblongata, and epinephrine was contained in midbrain and pons-medulla oblongata. On the other hand, in the various brain regions of transgenic mice, PNMT activity appeared and epinephrine was synthesized (Table 1 ; Fig. 4 A and B) . The epinephrine ratio, shown as a percentage of epinephrine content divided by the total content of norepinephrine and epinephrine, ranged from 2.6% to 9.1%. The PNMT activity in the pons-medulla oblongata is attributed to transgene products expressed in the cell bodies of the locus coeruleus and subcoeruleus complex, as shown by immunohistochemical analysis. The enzyme activities in other brain regions are attributed to the products localized in axon fibers and nerve terminals of these PNMT-containing neurons. Moreover, transgene products were unexpectedly expressed in some noncatecholaminergic neurons. However, expression of PNMT alone without other catecholaminesynthesizing enzymes in such cells would not contribute to epinephrine synthesis, and so the increase in epinephrine content depends on the correct expression of human PNMT in norepinephrine and epinephrine neurons.
We found the most pronounced changes in catecholamine synthesis in SCG and adrenal gland of the transgenic mice. Transgenic SCG generated high PNMT activity, which resulted in the appearance of epinephrine and a decrease in norepinephrine (Table 1 ; Fig. 4 C and D) . Norepinephrine was repressed to 40.5% of the control level, and the epinephrine ratio was 45.4%. In the adrenal gland of transgenic mice, PNMT activity was about 4-fold higher than that of nontransgenic control mice. Norepinephrine was reduced to only 4 PNMT in our analyses. Unexpectedly, transgene expression was also observed in some dopamine and noncatecholaminergic neurons. Since the results of immunohistochemical analysis of another transgenic line were almost the same as those obtained from the analysis of the DPN2-6 line, the position effect around the integration site of the transgene (26) cannot explain the ectopic expression of human PNMT. These results suggest that the 4-kb fragment containing the human DBH promoter may lack the additional information Our data indicate that PNMT expression in norepinephrine-producing cells can result in epinephrine production, and strongly suggest that norepinephrine-producing cells have (1992) the fundamental machinery necessary for epinephrine synthesis other than PNMT expression. Thus the only major difference between the norepinephrine-and epinephrineproducing cells is possibly the expression of PNMT. The intracellular synthesis of epinephrine proceeds via a complicated pathway mediated by a catecholamine-uptake system that is an active transporter coupled to an ATP-dependent ion pump (27, 28) . Dopamine produced in cytoplasm is transported into synaptic vesicles or adrenal medullary chromaffin vesicles, where DBH is localized and the dopamine is converted enzymatically to norepinephrine. Then, norepinephrine is released from the vesicles and epinephrine is synthesized by PNMT in the cytoplasm, although the mechanism of norepinephrine release is unknown. We therefore suppose that the additional PNMT expressed in the transgenic mice must synthesize epinephrine with cytoplasmic norepinephrine released from these vesicles.
The degree of epinephrine synthesis was different in various tissues of transgenic mice. In particular, all brain regions showed lower epinephrine ratios than peripheral tissues. We have at least three explanations for these results. (i) The amount of transgene product in a single cell may differ in each brain region. In another transgenic line, which revealed lower PNMT activity in the adrenal glands than DPN2-6, the epinephrine ratio seemed to be reduced in proportion to the enzyme activity, indicating that the expression level of the transgene is at least involved in the amount of the final product. (ii) In vivo PNMT activity may be regulated by the concentrations of norepinephrine and S-adenosyl-L-methionine, another substrate of PNMT (9), and by some posttranslational modification. (iii) The efficiency ofthe catecholamineuptake system might be an important factor in determining the relative ratios of norepinephrine and epinephrine. If norepinephrine were not efficiently released from vesicles, PNMT could not completely convert it to epinephrine, and both catecholamines could thus be stored in a single cell.
The switch of catecholamine phenotype in transgenic mice induced the emergence of epinephrine in the SCG and dynamic changes in the balance between norepinephrine and epinephrine in various brain regions, adrenal gland, and blood. In transgenic animals, the norepinephrine level decreased in the various catecholamine-containing tissues with the exception of the brain regions, whereas the epinephrine level was generally increased. Because catecholamines have important roles in a wide range of homeostatic regulation, we expected to find some effects on their physiological functions, such as carbohydrate metabolism and cardiovascular performance, in these transgenic mice. Our study of blood sugar and blood pressure in the normal breeding condition did not indicate any significant differences between transgenic and nontransgenic control mice. These physiological parameters in the normal breeding condition appear to be regulated by a complex mechanism to maintain their constant levels, although the catecholamine contents significantly changed in transgenic mice. Therefore, the effects derived from the catecholamine conversion should be clarified by more detailed analyses of the physiological conditions. For instance, study of blood pressure and blood sugar levels with adrenalectomized animals may be useful to emphasize the difference in sympathetic nerve function, and the response of these physiological levels against some stresses, such as cold stress and immobilization stress, should be examined.
Many investigators have reported the ligand-mediated modulation of adrenergic receptor. Catecholamine stimulation is followed by down-regulation or desensitization of adrenergic receptor, which generally involves receptor phosphorylation, decrease in receptor numbers, and uncoupling of receptor from the effector system (29) . On the other hand, the disruption of norepinephrine neurons with 6-hydroxydopa is known to elicit an increase in receptor numbers in postsynaptic membranes, suggesting the presence of a mechanism to compensate for the decrease in catecholamine input (30, 31) . In the transgenic mice described here, some changes in adrenergic receptor subtypes may be induced not only by the shift of norepinephrine and epinephrine levels but also by the appearance of epinephrine in the neurons that normally synthesize and secrete only norepinephrine. Our transgenic animals should also be useful in investigations of the regulatory mechanism of adrenergic receptors for changes in hormone and neurotransmitter levels.
